FDA OKs Lumateperone (Caplyta), First-in-Class for Schizophrenia FDA OKs Lumateperone (Caplyta), First-in-Class for Schizophrenia
Lumateperone (Caplyta) is a novel antipsychotic that acts synergistically through the serotonergic, dopaminergic, and glutamatergic systems.News Alerts
Source: Medscape Psychiatry Headlines - Category: Psychiatry Tags: Psychiatry News Alert Source Type: news
More News: Psychiatry | Schizophrenia